Search results for "Vegf pathway"

showing 3 items of 3 documents

Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors

2016

Angiogenesis is a key moment in tumor development and proliferation. Until recently oncologists did not know the mechanisms that were behind this phenomenon, but following the discoveries of Folkman and coworkers, they have gradually created and developed a series of drugs that act against angiogenesis by interacting with molecules belonging to the vascular endothelial growth factor (VEGFs) class and its receptors (VEGFRs) giving rise to anticancer effects. Tyrosine kinase inhibitors (TKIs) are a major class of these new anticancer agents, demonstrating high antitumor activity in a variety of "orphan" neoplasms (such as hepatocellular carcinoma, kidney cancer, sarcomas, etc.). The mechanism…

0301 basic medicineAngiogenesis; Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; VEGF; VEGF pathway; Medicine (all)Settore MED/06 - Oncologia MedicaAngiogenesisTyrosine kinase inhibitorPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVEGF pathwaymedicineReceptorCardiotoxicitybusiness.industryMedicine (all)medicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorAngiogenesiCardio-oncology030104 developmental biologyMechanism of actionchemistry030220 oncology & carcinogenesisHepatocellular carcinomamedicine.symptombusinessKidney cancerTyrosine kinase
researchProduct

Functional FLT1 genetic variation is a prognostic factor for recurrence in stage I-III non-small cell lung cancer

2015

Background: We propose that single-nucleotide polymorphisms (SNPs) in genes of the vascular endothelial growth factor pathway of angiogenesis will associate with survival in non-small-cell lung cancer (NSCLC) patients. Methods: Fifty-three SNPs in vascular endothelial growth factor-pathway genes were genotyped in 150 European stage I-III NSCLC patients and tested for associations with patient survival. Replication was performed in an independent cohort of 142 European stage I-III patients. Reporter gene assays were used to assess the effects of SNPs on transcriptional activity. Results: In the initial cohort, five SNPs associated (q < 0.05) with relapse-free survival (RFS). The minor allele…

MaleOncologyLung NeoplasmsAngiogenesisBioinformaticsmedicine.disease_causeCohort Studies0302 clinical medicineNon-small cell lung cancerVEGF pathwayCarcinoma Non-Small-Cell LungFLT1Aged 80 and over0303 health sciencesHazard ratioMiddle AgedPrognosis3. Good healthOncology030220 oncology & carcinogenesisFemaleKRASSNPsAdultPulmonary and Respiratory Medicinemedicine.medical_specialtySingle-nucleotide polymorphismPolymorphism Single NucleotideDisease-Free SurvivalArticle03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansNon–small cell lung cancerSNPLung cancerSurvival analysisAgedNeoplasm Staging030304 developmental biologyVascular Endothelial Growth Factor Receptor-1business.industryGenetic VariationMICROBIOLOGIAmedicine.diseaseSurvival AnalysisMinor allele frequencyNeoplasm Recurrence LocalbusinessEnhancer
researchProduct

ANGIOMET: Analysis of the correlations between angiogenic markers and outcome in patients (p) with advanced nonsquamous NSCLC (NS-NSCLC) treated with…

2014

e19014 Background: In NS-NSCLC CPB achieved median OS > 1 y and supported use of B. A broad range of predictive/prognostic markers explored for B use. In VEGF pathway ligands and receptors play an ...

OncologyCancer Researchmedicine.medical_specialtyBevacizumabbusiness.industryCarboplatin/paclitaxelOncologyVegf pathwayInternal medicinemedicineIn patientbusinessReceptormedicine.drugJournal of Clinical Oncology
researchProduct